You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameArgatroban
Accession NumberDB00278  (APRD00105)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionArgatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Argatrobaninjection1 mg/mLintravenousSandoz Inc2011-09-06Not applicableUs
Argatrobaninjection, solution100 mg/mLintravenousGlaxo Smith Kline Llc2000-11-28Not applicableUs
Argatrobaninjection, solution1 mg/mLintravenousTeva Parenteral Medicines, Inc.2015-04-27Not applicableUs
Argatrobaninjection1 mg/mLintravenousEagle Pharmaceuticals, Inc.2011-09-06Not applicableUs
Argatrobaninjection, solution100 mg/mLintravenousFresenius Kabi USA, LLC2015-03-17Not applicableUs
Argatrobansolution125 mg/125mLintravenousSandoz Inc2011-05-09Not applicableUs
Argatrobaninjection1 mg/mLintravenousEagle Pharmaceuticals, Inc.2011-09-06Not applicableUs
Argatrobansolution100 mgintravenousPfizer Canada Inc2002-06-13Not applicableCanada
Argatrobaninjection1 mg/mLintravenousSandoz Inc2011-09-06Not applicableUs
Argatrobaninjection250 mg/2.5mLintravenousWest Ward Pharmaceuticals Corp2012-01-05Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Argatrobaninjection250 mg/2.5mLintravenousPar Pharmaceutical, Inc.2015-06-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Argatroban monohydrate
141396-28-3
Thumb
  • InChI Key: AIEZTKLTLCMZIA-CZSXTPSTSA-N
  • Monoisotopic Mass: 526.257354142
  • Average Mass: 526.65
DBSALT001826
Categories
UNIIOCY3U280Y3
CAS number74863-84-6
WeightAverage: 508.634
Monoisotopic: 508.246788982
Chemical FormulaC23H36N6O5S
InChI KeyInChIKey=KXNPVXPOPUZYGB-XYVMCAHJSA-N
InChI
InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15-,17+,18-/m1/s1
IUPAC Name
(2R,4R)-1-[(2S)-5-[(diaminomethylidene)amino]-2-[(3R)-3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonamido]pentanoyl]-4-methylpiperidine-2-carboxylic acid
SMILES
C[C@@H]1CCN([[email protected]](C1)C(O)=O)C(=O)[[email protected]](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[[email protected]](C)C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • Alpha-amino acid amide
  • Tetrahydroquinoline
  • Benzenesulfonamide
  • Alpha-amino acid or derivatives
  • Piperidinecarboxylic acid
  • N-acyl-piperidine
  • Aralkylamine
  • Secondary aliphatic/aromatic amine
  • Benzenoid
  • Piperidine
  • Aminosulfonyl compound
  • Tertiary carboxylic acid amide
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Tertiary amine
  • Guanidine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationArgatroban is indicated for prevention and treatment of thrombosis caused by heparin induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.
PharmacodynamicsArgatroban is a synthetic direct thrombin inhibitor derived from L-arginine indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban does not require the co-factor antithrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation. Argatroban is highly selective for thrombin with an inhibitory constant (Ki) of 0.04 µM. At therapeutic concentrations, Argatroban has little or no effect on related serine proteases (trypsin, factor Xa, plasmin, and kallikrein). Argatroban is capable of inhibiting the action of both free and clot-associated thrombin.
Mechanism of actionArgatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation.
Related Articles
AbsorptionBioavailability is 100% (intravenous).
Volume of distribution
  • 174 mL/kg
  • 12.18 L [70-kg adult]
Protein binding54%
Metabolism

Liver via hydroxylation and aromatization of the 3-methyltetrahydroquinoline ring. Age and gender do not substantially affect the pharmacodynamic or pharmacokinetic profile of argatroban.

Route of eliminationArgatroban is excreted primarily in the feces (65%), presumably through biliary secretion; 22% is eliminated via urine.
Half life39 and 51 minutes
Clearance
  • 5.1 L/kg/hr [infusion doses up to 40 mcg/kg/min]
ToxicityExcessive bleeding
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Argatroban Action PathwayDrug actionSMP00276
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6195
Blood Brain Barrier-0.8933
Caco-2 permeable-0.7293
P-glycoprotein substrateSubstrate0.8193
P-glycoprotein inhibitor INon-inhibitor0.6701
P-glycoprotein inhibitor IINon-inhibitor0.6802
Renal organic cation transporterNon-inhibitor0.8147
CYP450 2C9 substrateNon-substrate0.5571
CYP450 2D6 substrateNon-substrate0.8861
CYP450 3A4 substrateNon-substrate0.5477
CYP450 1A2 substrateNon-inhibitor0.8849
CYP450 2C9 inhibitorNon-inhibitor0.662
CYP450 2D6 inhibitorNon-inhibitor0.8789
CYP450 2C19 inhibitorNon-inhibitor0.7706
CYP450 3A4 inhibitorNon-inhibitor0.8316
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9636
Ames testNon AMES toxic0.6238
CarcinogenicityNon-carcinogens0.7551
BiodegradationNot ready biodegradable0.9966
Rat acute toxicity1.5767 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9833
hERG inhibition (predictor II)Non-inhibitor0.6071
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
Packagers
Dosage forms
FormRouteStrength
Injectionintravenous1 mg/mL
Injectionintravenous250 mg/2.5mL
Injection, solutionintravenous1 mg/mL
Injection, solutionintravenous100 mg/mL
Solutionintravenous100 mg
Solutionintravenous125 mg/125mL
Prices
Unit descriptionCostUnit
Argatroban 100 mg/ml Solution 2.5ml Vial1546.46USD vial
Argatroban 100 mg/ml vial743.49USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5214052 No1994-06-302014-06-30Us
US7589106 No2007-09-262027-09-26Us
US7687516 No2007-09-262027-09-26Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.221 mg/mLALOGPS
logP0.19ALOGPS
logP-0.97ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)3.07ChemAxon
pKa (Strongest Basic)10.91ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area180.21 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity133.54 m3·mol-1ChemAxon
Polarizability53.9 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Tomiya Mano, Jin Shiomura, “Argatroban preparations for ophthalmic use.” U.S. Patent US5506241, issued October, 1986.

US5506241
General References
  1. Di Nisio M, Middeldorp S, Buller HR: Direct thrombin inhibitors. N Engl J Med. 2005 Sep 8;353(10):1028-40. [PubMed:16148288 ]
External Links
ATC CodesB01AE03
AHFS Codes
  • 20:12.04.12
PDB EntriesNot Available
FDA labelDownload (83.7 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Argatroban.
AbciximabAbciximab may increase the anticoagulant activities of Argatroban.
AceclofenacAceclofenac may increase the anticoagulant activities of Argatroban.
AcenocoumarolArgatroban may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Argatroban.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Argatroban is combined with Acetylsalicylic acid.
AdapaleneAdapalene may increase the anticoagulant activities of Argatroban.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Argatroban.
AllylestrenolThe therapeutic efficacy of Argatroban can be decreased when used in combination with Allylestrenol.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Argatroban.
AlprostadilAlprostadil may increase the anticoagulant activities of Argatroban.
AlprostadilArgatroban may increase the antiplatelet activities of Alprostadil.
AlteplaseAlteplase may increase the anticoagulant activities of Argatroban.
AltrenogestThe therapeutic efficacy of Argatroban can be decreased when used in combination with Altrenogest.
ALX-0081ALX-0081 may increase the anticoagulant activities of Argatroban.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Argatroban.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Argatroban.
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Argatroban.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Argatroban is combined with Aminosalicylic Acid.
AmiodaroneThe metabolism of Argatroban can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Argatroban.
AnagrelideAnagrelide may increase the anticoagulant activities of Argatroban.
AncrodArgatroban may increase the anticoagulant activities of Ancrod.
AnistreplaseAnistreplase may increase the anticoagulant activities of Argatroban.
AntipyrineAntipyrine may increase the anticoagulant activities of Argatroban.
Antithrombin III humanArgatroban may increase the anticoagulant activities of Antithrombin III human.
ApixabanApixaban may increase the anticoagulant activities of Argatroban.
ApremilastApremilast may increase the anticoagulant activities of Argatroban.
AprepitantThe serum concentration of Argatroban can be increased when it is combined with Aprepitant.
AprotininThe therapeutic efficacy of Argatroban can be decreased when used in combination with Aprotinin.
ArdeparinArgatroban may increase the anticoagulant activities of Ardeparin.
AstaxanthinAstaxanthin may increase the anticoagulant activities of Argatroban.
AtazanavirThe metabolism of Argatroban can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Argatroban can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Argatroban.
AzapropazoneAzapropazone may increase the anticoagulant activities of Argatroban.
AzelastineAzelastine may increase the anticoagulant activities of Argatroban.
AzelastineArgatroban may increase the antiplatelet activities of Azelastine.
BalsalazideBalsalazide may increase the anticoagulant activities of Argatroban.
BatroxobinBatroxobin may increase the anticoagulant activities of Argatroban.
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Argatroban.
BecaplerminBecaplermin may increase the anticoagulant activities of Argatroban.
BemiparinBemiparin may increase the anticoagulant activities of Argatroban.
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Argatroban.
BeraprostBeraprost may increase the anticoagulant activities of Argatroban.
BexaroteneThe serum concentration of Argatroban can be decreased when it is combined with Bexarotene.
BivalirudinBivalirudin may increase the anticoagulant activities of Argatroban.
BoceprevirThe serum concentration of Argatroban can be decreased when it is combined with Boceprevir.
BortezomibThe metabolism of Argatroban can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Argatroban can be decreased when it is combined with Bosentan.
BromfenacBromfenac may increase the anticoagulant activities of Argatroban.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Argatroban.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Argatroban.
CangrelorCangrelor may increase the anticoagulant activities of Argatroban.
CarbamazepineThe metabolism of Argatroban can be increased when combined with Carbamazepine.
CarprofenCarprofen may increase the anticoagulant activities of Argatroban.
CastanospermineCastanospermine may increase the anticoagulant activities of Argatroban.
CelecoxibCelecoxib may increase the anticoagulant activities of Argatroban.
CeritinibThe serum concentration of Argatroban can be increased when it is combined with Ceritinib.
CertoparinArgatroban may increase the anticoagulant activities of Certoparin.
ChloroquineChloroquine may increase the anticoagulant activities of Argatroban.
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Argatroban.
CilostazolCilostazol may increase the anticoagulant activities of Argatroban.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Argatroban.
Citric AcidArgatroban may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Argatroban.
ClarithromycinThe metabolism of Argatroban can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Argatroban can be decreased when combined with Clemastine.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Argatroban.
ClonixinClonixin may increase the anticoagulant activities of Argatroban.
ClopidogrelClopidogrel may increase the anticoagulant activities of Argatroban.
ClotrimazoleThe metabolism of Argatroban can be decreased when combined with Clotrimazole.
CobicistatThe metabolism of Argatroban can be decreased when combined with Cobicistat.
CollagenaseThe risk or severity of adverse effects can be increased when Argatroban is combined with Collagenase.
ConivaptanThe serum concentration of Argatroban can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensConjugated Equine Estrogens may decrease the anticoagulant activities of Argatroban.
CrizotinibThe metabolism of Argatroban can be decreased when combined with Crizotinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Argatroban.
CyclophosphamideThe risk or severity of adverse effects can be increased when Argatroban is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Argatroban.
CyclosporineThe metabolism of Argatroban can be decreased when combined with Cyclosporine.
D-LimoneneD-Limonene may increase the anticoagulant activities of Argatroban.
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Argatroban.
DabrafenibThe serum concentration of Argatroban can be decreased when it is combined with Dabrafenib.
DalteparinArgatroban may increase the anticoagulant activities of Dalteparin.
DanaparoidArgatroban may increase the anticoagulant activities of Danaparoid.
DarunavirThe metabolism of Argatroban can be decreased when combined with Darunavir.
DasatinibDasatinib may increase the anticoagulant activities of Argatroban.
DeferasiroxThe risk or severity of adverse effects can be increased when Argatroban is combined with Deferasirox.
DeferasiroxThe serum concentration of Argatroban can be decreased when it is combined with Deferasirox.
DefibrotideDefibrotide may increase the anticoagulant activities of Argatroban.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Argatroban.
DelavirdineThe metabolism of Argatroban can be decreased when combined with Delavirdine.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Argatroban is combined with Deoxycholic Acid.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Argatroban.
DesirudinArgatroban may increase the anticoagulant activities of Desirudin.
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Argatroban.
DesogestrelThe therapeutic efficacy of Argatroban can be decreased when used in combination with Desogestrel.
DexamethasoneThe serum concentration of Argatroban can be decreased when it is combined with Dexamethasone.
DextranArgatroban may increase the anticoagulant activities of Dextran.
Dextran 40Argatroban may increase the anticoagulant activities of Dextran 40.
Dextran 70Argatroban may increase the anticoagulant activities of Dextran 70.
Dextran 75Argatroban may increase the anticoagulant activities of Dextran 75.
DiclofenacDiclofenac may increase the anticoagulant activities of Argatroban.
DicoumarolDicoumarol may increase the anticoagulant activities of Argatroban.
DienestrolDienestrol may decrease the anticoagulant activities of Argatroban.
DienogestThe therapeutic efficacy of Argatroban can be decreased when used in combination with Dienogest.
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Argatroban.
DiflunisalDiflunisal may increase the anticoagulant activities of Argatroban.
DiflunisalThe risk or severity of adverse effects can be increased when Argatroban is combined with Diflunisal.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Argatroban.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Argatroban.
DihydroergotamineThe metabolism of Argatroban can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Argatroban can be decreased when combined with Diltiazem.
DipyridamoleDipyridamole may increase the anticoagulant activities of Argatroban.
DitazoleDitazole may increase the anticoagulant activities of Argatroban.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Argatroban.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Argatroban.
DoxycyclineThe metabolism of Argatroban can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Argatroban can be decreased when combined with Dronedarone.
DrospirenoneThe therapeutic efficacy of Argatroban can be decreased when used in combination with Drospirenone.
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Argatroban.
DroxicamDroxicam may increase the anticoagulant activities of Argatroban.
DydrogesteroneThe therapeutic efficacy of Argatroban can be decreased when used in combination with Dydrogesterone.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Argatroban.
Edetic AcidArgatroban may increase the anticoagulant activities of Edetic Acid.
EdoxabanEdoxaban may increase the anticoagulant activities of Argatroban.
EfavirenzThe serum concentration of Argatroban can be decreased when it is combined with Efavirenz.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Argatroban.
EnoxaparinArgatroban may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Argatroban can be decreased when it is combined with Enzalutamide.
EpinastineEpinastine may increase the anticoagulant activities of Argatroban.
EpinastineArgatroban may increase the antiplatelet activities of Epinastine.
EpirizoleEpirizole may increase the anticoagulant activities of Argatroban.
EpoprostenolEpoprostenol may increase the anticoagulant activities of Argatroban.
EptifibatideEptifibatide may increase the anticoagulant activities of Argatroban.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Argatroban.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Argatroban.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Argatroban.
ErythromycinThe metabolism of Argatroban can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Argatroban can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Argatroban.
EstradiolEstradiol may decrease the anticoagulant activities of Argatroban.
EstriolEstriol may decrease the anticoagulant activities of Argatroban.
EstroneEstrone may decrease the anticoagulant activities of Argatroban.
EtanerceptEtanercept may increase the anticoagulant activities of Argatroban.
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Argatroban.
Ethyl biscoumacetateArgatroban may increase the anticoagulant activities of Ethyl biscoumacetate.
EtodolacEtodolac may increase the anticoagulant activities of Argatroban.
EtofenamateEtofenamate may increase the anticoagulant activities of Argatroban.
EtonogestrelThe therapeutic efficacy of Argatroban can be decreased when used in combination with Etonogestrel.
EtoricoxibEtoricoxib may increase the anticoagulant activities of Argatroban.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Argatroban.
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Argatroban.
exisulindexisulind may increase the anticoagulant activities of Argatroban.
FenbufenFenbufen may increase the anticoagulant activities of Argatroban.
FenoprofenFenoprofen may increase the anticoagulant activities of Argatroban.
FibrinolysinFibrinolysin may increase the anticoagulant activities of Argatroban.
FloctafenineFloctafenine may increase the anticoagulant activities of Argatroban.
FluconazoleThe metabolism of Argatroban can be decreased when combined with Fluconazole.
FlunixinFlunixin may increase the anticoagulant activities of Argatroban.
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Argatroban.
FluvoxamineThe metabolism of Argatroban can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumArgatroban may increase the anticoagulant activities of Fondaparinux sodium.
FosamprenavirThe metabolism of Argatroban can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Argatroban can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Argatroban can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Argatroban can be increased when it is combined with Fusidic Acid.
GarlicThe serum concentration of Argatroban can be decreased when it is combined with Garlic.
GenisteinGenistein may decrease the anticoagulant activities of Argatroban.
GestodeneThe therapeutic efficacy of Argatroban can be decreased when used in combination with Gestodene.
GlucosamineGlucosamine may increase the antiplatelet activities of Argatroban.
HeminHemin may increase the anticoagulant activities of Argatroban.
HeparinArgatroban may increase the anticoagulant activities of Heparin.
HexestrolHexestrol may decrease the anticoagulant activities of Argatroban.
HirulogArgatroban may increase the anticoagulant activities of Hirulog.
HMPL-004HMPL-004 may increase the anticoagulant activities of Argatroban.
Hydroxyprogesterone caproateThe therapeutic efficacy of Argatroban can be decreased when used in combination with Hydroxyprogesterone caproate.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Argatroban is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Argatroban.
IbudilastIbudilast may increase the anticoagulant activities of Argatroban.
IbudilastArgatroban may increase the antiplatelet activities of Ibudilast.
IbuprofenIbuprofen may increase the anticoagulant activities of Argatroban.
IbuproxamIbuproxam may increase the anticoagulant activities of Argatroban.
IcatibantIcatibant may increase the anticoagulant activities of Argatroban.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Argatroban.
Icosapent ethylArgatroban may increase the antiplatelet activities of Icosapent ethyl.
IdelalisibThe serum concentration of Argatroban can be increased when it is combined with Idelalisib.
IfenprodilIfenprodil may increase the anticoagulant activities of Argatroban.
IfenprodilArgatroban may increase the antiplatelet activities of Ifenprodil.
IloprostIloprost may increase the anticoagulant activities of Argatroban.
ImatinibThe metabolism of Argatroban can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Argatroban.
IndinavirThe metabolism of Argatroban can be decreased when combined with Indinavir.
IndomethacinIndomethacin may increase the anticoagulant activities of Argatroban.
IndoprofenIndoprofen may increase the anticoagulant activities of Argatroban.
IsavuconazoniumThe metabolism of Argatroban can be decreased when combined with Isavuconazonium.
IsoxicamIsoxicam may increase the anticoagulant activities of Argatroban.
IsradipineThe metabolism of Argatroban can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Argatroban can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Argatroban can be increased when it is combined with Ivacaftor.
KebuzoneKebuzone may increase the anticoagulant activities of Argatroban.
KetoconazoleThe metabolism of Argatroban can be decreased when combined with Ketoconazole.
KetoprofenKetoprofen may increase the anticoagulant activities of Argatroban.
KetorolacKetorolac may increase the anticoagulant activities of Argatroban.
LeflunomideLeflunomide may increase the anticoagulant activities of Argatroban.
LepirudinLepirudin may increase the anticoagulant activities of Argatroban.
LevonorgestrelThe therapeutic efficacy of Argatroban can be decreased when used in combination with Levonorgestrel.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Argatroban.
LopinavirThe metabolism of Argatroban can be decreased when combined with Lopinavir.
LornoxicamLornoxicam may increase the anticoagulant activities of Argatroban.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Argatroban.
LovastatinThe metabolism of Argatroban can be decreased when combined with Lovastatin.
LoxoprofenLoxoprofen may increase the anticoagulant activities of Argatroban.
LuliconazoleThe serum concentration of Argatroban can be increased when it is combined with Luliconazole.
LumiracoxibLumiracoxib may increase the anticoagulant activities of Argatroban.
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Argatroban.
MasoprocolMasoprocol may increase the anticoagulant activities of Argatroban.
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Argatroban.
MedrogestoneThe therapeutic efficacy of Argatroban can be decreased when used in combination with Medrogestone.
Medroxyprogesterone acetateThe therapeutic efficacy of Argatroban can be decreased when used in combination with Medroxyprogesterone acetate.
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Argatroban.
Megestrol acetateThe therapeutic efficacy of Argatroban can be decreased when used in combination with Megestrol acetate.
MeloxicamMeloxicam may increase the anticoagulant activities of Argatroban.
MesalazineMesalazine may increase the anticoagulant activities of Argatroban.
MesalazineThe risk or severity of adverse effects can be increased when Argatroban is combined with Mesalazine.
MestranolMestranol may decrease the anticoagulant activities of Argatroban.
MetamizoleMetamizole may increase the anticoagulant activities of Argatroban.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Argatroban.
MifepristoneThe metabolism of Argatroban can be decreased when combined with Mifepristone.
MilrinoneMilrinone may increase the anticoagulant activities of Argatroban.
MilrinoneArgatroban may increase the antiplatelet activities of Milrinone.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Argatroban.
MitotaneThe serum concentration of Argatroban can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Argatroban can be decreased when it is combined with Modafinil.
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Argatroban.
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Argatroban.
NabumetoneNabumetone may increase the anticoagulant activities of Argatroban.
NadroparinArgatroban may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Argatroban can be decreased when it is combined with Nafcillin.
NaftifineNaftifine may increase the anticoagulant activities of Argatroban.
NaproxenNaproxen may increase the anticoagulant activities of Argatroban.
NCX 4016NCX 4016 may increase the anticoagulant activities of Argatroban.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Argatroban.
NefazodoneThe metabolism of Argatroban can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Argatroban can be decreased when combined with Nelfinavir.
NepafenacNepafenac may increase the anticoagulant activities of Argatroban.
NetupitantThe serum concentration of Argatroban can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Argatroban can be decreased when combined with Nevirapine.
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Argatroban.
NilotinibThe metabolism of Argatroban can be decreased when combined with Nilotinib.
NimesulideNimesulide may increase the anticoagulant activities of Argatroban.
NimesulideArgatroban may increase the antiplatelet activities of Nimesulide.
NintedanibThe risk or severity of adverse effects can be increased when Argatroban is combined with Nintedanib.
NorethisteroneThe therapeutic efficacy of Argatroban can be decreased when used in combination with Norethisterone.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Argatroban.
ObinutuzumabThe risk or severity of adverse effects can be increased when Argatroban is combined with Obinutuzumab.
OlaparibThe metabolism of Argatroban can be decreased when combined with Olaparib.
OlopatadineOlopatadine may increase the anticoagulant activities of Argatroban.
OlsalazineOlsalazine may increase the anticoagulant activities of Argatroban.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Argatroban is combined with Omacetaxine mepesuccinate.
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Argatroban.
OrgoteinOrgotein may increase the anticoagulant activities of Argatroban.
OsimertinibThe serum concentration of Argatroban can be increased when it is combined with Osimertinib.
OtamixabanArgatroban may increase the anticoagulant activities of Otamixaban.
OxaprozinOxaprozin may increase the anticoagulant activities of Argatroban.
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Argatroban.
PalbociclibThe serum concentration of Argatroban can be increased when it is combined with Palbociclib.
ParecoxibParecoxib may increase the anticoagulant activities of Argatroban.
ParnaparinParnaparin may increase the anticoagulant activities of Argatroban.
PentobarbitalThe metabolism of Argatroban can be increased when combined with Pentobarbital.
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Argatroban.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Argatroban.
PethidineThe risk or severity of adverse effects can be increased when Argatroban is combined with Pethidine.
PhenindioneArgatroban may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Argatroban can be increased when combined with Phenobarbital.
PhenprocoumonArgatroban may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Argatroban.
PhenytoinThe metabolism of Argatroban can be increased when combined with Phenytoin.
PimecrolimusPimecrolimus may increase the anticoagulant activities of Argatroban.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Argatroban.
PirfenidonePirfenidone may increase the anticoagulant activities of Argatroban.
PiroxicamPiroxicam may increase the anticoagulant activities of Argatroban.
PlasminPlasmin may increase the anticoagulant activities of Argatroban.
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Argatroban.
PosaconazoleThe metabolism of Argatroban can be decreased when combined with Posaconazole.
PrasugrelPrasugrel may increase the anticoagulant activities of Argatroban.
PrimidoneThe metabolism of Argatroban can be increased when combined with Primidone.
ProgesteroneThe therapeutic efficacy of Argatroban can be decreased when used in combination with Progesterone.
PropacetamolPropacetamol may increase the anticoagulant activities of Argatroban.
Protein CArgatroban may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeArgatroban may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Argatroban.
PTC299PTC299 may increase the anticoagulant activities of Argatroban.
QuinestrolQuinestrol may decrease the anticoagulant activities of Argatroban.
RanolazineThe metabolism of Argatroban can be decreased when combined with Ranolazine.
ResveratrolResveratrol may increase the anticoagulant activities of Argatroban.
ResveratrolArgatroban may increase the antiplatelet activities of Resveratrol.
ReteplaseReteplase may increase the anticoagulant activities of Argatroban.
ReviparinArgatroban may increase the anticoagulant activities of Reviparin.
RidogrelRidogrel may increase the anticoagulant activities of Argatroban.
RidogrelArgatroban may increase the antiplatelet activities of Ridogrel.
RifabutinThe metabolism of Argatroban can be increased when combined with Rifabutin.
RifampicinThe metabolism of Argatroban can be increased when combined with Rifampicin.
RifapentineThe metabolism of Argatroban can be increased when combined with Rifapentine.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Argatroban.
RitonavirThe metabolism of Argatroban can be decreased when combined with Ritonavir.
RivaroxabanArgatroban may increase the anticoagulant activities of Rivaroxaban.
RofecoxibRofecoxib may increase the anticoagulant activities of Argatroban.
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Argatroban.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Argatroban.
SalicylamideSalicylamide may increase the anticoagulant activities of Argatroban.
Salicylic acidSalicylic acid may increase the anticoagulant activities of Argatroban.
Salicylic acidThe risk or severity of adverse effects can be increased when Argatroban is combined with Salicylic acid.
SalsalateSalsalate may increase the anticoagulant activities of Argatroban.
SaquinavirThe metabolism of Argatroban can be decreased when combined with Saquinavir.
SCH-530348SCH-530348 may increase the anticoagulant activities of Argatroban.
SCH-530348Argatroban may increase the antiplatelet activities of SCH-530348.
SelexipagSelexipag may increase the anticoagulant activities of Argatroban.
SeratrodastSeratrodast may increase the anticoagulant activities of Argatroban.
SevofluraneSevoflurane may increase the anticoagulant activities of Argatroban.
SevofluraneArgatroban may increase the antiplatelet activities of Sevoflurane.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Argatroban.
SildenafilThe metabolism of Argatroban can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Argatroban can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Argatroban can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Argatroban.
SRT501SRT501 may increase the anticoagulant activities of Argatroban.
SRT501Argatroban may increase the antiplatelet activities of SRT501.
St. John's WortThe metabolism of Argatroban can be increased when combined with St. John's Wort.
StiripentolThe serum concentration of Argatroban can be increased when it is combined with Stiripentol.
StreptokinaseStreptokinase may increase the anticoagulant activities of Argatroban.
SugammadexSugammadex may increase the anticoagulant activities of Argatroban.
SulfasalazineSulfasalazine may increase the anticoagulant activities of Argatroban.
SulfisoxazoleThe metabolism of Argatroban can be decreased when combined with Sulfisoxazole.
SulindacSulindac may increase the anticoagulant activities of Argatroban.
SulodexideArgatroban may increase the anticoagulant activities of Sulodexide.
SuprofenSuprofen may increase the anticoagulant activities of Argatroban.
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Argatroban.
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Argatroban.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Argatroban.
TelaprevirThe metabolism of Argatroban can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Argatroban can be decreased when combined with Telithromycin.
TemsirolimusThe risk or severity of adverse effects can be increased when Argatroban is combined with Temsirolimus.
TenecteplaseTenecteplase may increase the anticoagulant activities of Argatroban.
TenoxicamTenoxicam may increase the anticoagulant activities of Argatroban.
TepoxalinTepoxalin may increase the anticoagulant activities of Argatroban.
TeriflunomideTeriflunomide may increase the anticoagulant activities of Argatroban.
TesmilifeneTesmilifene may increase the anticoagulant activities of Argatroban.
TesmilifeneArgatroban may increase the antiplatelet activities of Tesmilifene.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Argatroban.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Argatroban.
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Argatroban.
TiboloneTibolone may increase the anticoagulant activities of Argatroban.
TicagrelorTicagrelor may increase the anticoagulant activities of Argatroban.
TiclopidineTiclopidine may increase the anticoagulant activities of Argatroban.
TinzaparinTinzaparin may increase the anticoagulant activities of Argatroban.
TipranavirThe serum concentration of Argatroban can be decreased when it is combined with Tipranavir.
TirofibanTirofiban may increase the anticoagulant activities of Argatroban.
TocilizumabThe serum concentration of Argatroban can be decreased when it is combined with Tocilizumab.
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Argatroban.
TolmetinTolmetin may increase the anticoagulant activities of Argatroban.
TositumomabThe risk or severity of adverse effects can be increased when Argatroban is combined with Tositumomab.
TranilastTranilast may increase the anticoagulant activities of Argatroban.
TranilastArgatroban may increase the antiplatelet activities of Tranilast.
TrapidilTrapidil may increase the anticoagulant activities of Argatroban.
TrapidilArgatroban may increase the antiplatelet activities of Trapidil.
TreprostinilTreprostinil may increase the anticoagulant activities of Argatroban.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Argatroban.
TriflusalTriflusal may increase the anticoagulant activities of Argatroban.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Argatroban.
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Argatroban.
UrokinaseUrokinase may increase the anticoagulant activities of Argatroban.
ValdecoxibValdecoxib may increase the anticoagulant activities of Argatroban.
VenlafaxineThe metabolism of Argatroban can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Argatroban can be decreased when combined with Verapamil.
Vitamin EVitamin E may increase the anticoagulant activities of Argatroban.
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Argatroban.
VorapaxarArgatroban may increase the anticoagulant activities of Vorapaxar.
VoriconazoleThe metabolism of Argatroban can be decreased when combined with Voriconazole.
WarfarinArgatroban may increase the anticoagulant activities of Warfarin.
XimelagatranArgatroban may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Argatroban.
ZeranolZeranol may decrease the anticoagulant activities of Argatroban.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Argatroban.
ZileutonZileuton may increase the anticoagulant activities of Argatroban.
ZiprasidoneThe metabolism of Argatroban can be decreased when combined with Ziprasidone.
ZomepiracZomepirac may increase the anticoagulant activities of Argatroban.
Food Interactions
  • Herbs and food with anticoagulant/antiplatelet activity. Major interactions may occur with danshen, dong quai, evening primrose oil, gingko, policosanol, willow bark

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Thrombospondin receptor activity
Specific Function:
Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.
Gene Name:
F2
Uniprot ID:
P00734
Molecular Weight:
70036.295 Da
References
  1. Kawada T, Okada Y, Hoson M, Endo S, Yokoyama M, Kitanaka Y, Kimura K, Abe H, Yamate N: Argatroban, an attractive anticoagulant, for left heart bypass with centrifugal pump for repair of traumatic aortic rupture. Jpn J Thorac Cardiovasc Surg. 1999 Mar;47(3):104-9. [PubMed:10226408 ]
  2. Sakai M, Ohteki H, Narita Y, Naitoh K, Natsuaki M, Itoh T: Argatroban as a potential anticoagulant in cardiopulmonary bypass-studies in a dog model. Cardiovasc Surg. 1999 Mar;7(2):187-94. [PubMed:10353669 ]
  3. Jang IK, Brown DF, Giugliano RP, Anderson HV, Losordo D, Nicolau JC, Dutra OP, Bazzino O, Viamonte VM, Norbady R, Liprandi AS, Massey TJ, Dinsmore R, Schwarz RP Jr: A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol. 1999 Jun;33(7):1879-85. [PubMed:10362188 ]
  4. Matsuo T, Kario K, Matsuda S, Yamaguchi N, Kakishita E: Effect of Thrombin Inhibition on Patients with Peripheral Arterial Obstructive Disease: A Multicenter Clinical Trial of Argatroban. J Thromb Thrombolysis. 1995;2(2):131-136. [PubMed:10608016 ]
  5. Serebruany VL, Jang IK, Giugliano RP, Massey TJ, Schwarz Jr RP: A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocardial Infarction using Novastan(R) and T-PA (MINT) Study. J Thromb Thrombolysis. 1998;5(1):49-52. [PubMed:10608050 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 01, 2016 02:24